Global Diabetes Drugs Market - 2025 - 2032

The global diabetes drugs market reached US$ 78.11 billion in 2024 and is expected to reach US$ 141.73 billion by 2032, growing at a CAGR of 7.8 % during the forecast period 2025-2032.

Diabetes is a chronic condition that arises when the pancreas either fails to produce sufficient insulin or when the body cannot effectively utilize the insulin it produces. Insulin is a hormone essential for regulating blood glucose levels. When diabetes is uncontrolled, it can lead to hyperglycemia, commonly referred to as elevated blood sugar levels. Over time, hyperglycemia can cause significant damage to various bodily systems, particularly affecting nerves and blood vessels.

Diabetes drugs are essential for managing blood glucose levels in individuals with diabetes, helping to mitigate the risk of serious complications such as cardiovascular disease, kidney failure, nerve damage, and vision problems. The choice of medication is influenced by several factors, including the type of diabetes (Type 1 or Type 2), the patient's overall health status, and their response to various treatments.

According to the World Health Organization (WHO) data in 2022, approximately 14% of adults aged 18 and older were living with diabetes, a notable increase from 7% in 1990. Alarmingly, more than half (59%) of adults aged 30 and over diagnosed with diabetes were not receiving medication for their condition in 2022. Furthermore, diabetes treatment coverage was particularly low in low- and middle-income countries.

The impact of diabetes on health is severe in 2021, it was directly responsible for 1.6 million deaths, with 47% of these fatalities occurring in individuals under the age of 70. Additionally, diabetes contributed to another 530,000 deaths due to kidney disease and was linked to approximately 11% of cardiovascular-related deaths. These factors have driven the global diabetes drugs market expansion.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The rising prevalence of diabetes is significantly driving the growth of the global diabetes drugs market and is expected to drive throughout the market forecast period.

The increase in Type 2 diabetes cases driven by obesity rates and lifestyle changes is a primary factor fueling the growth of the global diabetes drugs market.

Global Diabetes Epidemiology

According to the International Diabetes Federation (IDF) reported data in 2021, 10.5% of adults aged 20 to 79 were living with diabetes, which translates to approximately 530 million individuals. This figure is anticipated to rise to 783 million by 2045, equating to about 1 in 8 adults, marking a 46% increase in prevalence. All these factors demand the global diabetes drugs market.

Moreover, key player's product launches & approvals, and advancements in diabetes management drive this diabetes drugs market growth. For instance, in January 2024, Dong-A ST launched a new combination drug aimed at treating type 2 diabetes, which is a significant advancement in diabetes management. This fixed-dose combination (FDC) drug combines three active ingredients: Teneligliptin, Dapagliflozin, and Metformin. This combination is designed to improve glycemic control in patients with type 2 diabetes, particularly those with high HbA1c levels and other co-morbidities such as hypertension or cardiovascular issues.

Similarly, in October 2023, Zydus Lifesciences Limited announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ZITUVIO (Sitagliptin) tablets, available in dosages of 25 mg, 50 mg, and 100 mg. ZITUVIO contains sitagliptin, which is classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It is indicated to be used alongside diet and exercise to help improve glycemic control in adults diagnosed with type 2 diabetes mellitus.

Also, in April 2022, Glenmark Pharmaceuticals introduced a novel fixed-dose combination (FDC) of the DPP4 inhibitor Teneligliptin and the thiazolidinedione (TZD) Pioglitazone. This FDC, marketed under the brand name Zita Plus Pio, contains Teneligliptin 20 mg and Pioglitazone 15 mg, to be taken once daily. It is the only available DPP4 and glitazone combination in India for managing uncontrolled type 2 diabetes in adults. All these factors demand the global diabetes drugs market.

Moreover, the rising demand for advancements in diabetes treatment contributes to the global diabetes drugs market expansion.

High Cost of Diabetes Medications

The high cost of diabetes medications represents a major barrier in the global diabetes drugs market, restricting access to vital treatments for many patients. To tackle this issue, policymakers, healthcare providers, and pharmaceutical companies need to collaborate to enhance affordability and ensure that all individuals living with diabetes have access to the necessary medications for the effective management of their condition.

The high cost of diabetes medications disproportionately affects uninsured and low-income populations. Many individuals living with diabetes may not have adequate health insurance coverage or face high out-of-pocket expenses that make treatment unaffordable. According to the American Diabetes Association, spending on insulin has tripled over the past decade, rising from $8 billion in 2012 to $22.3 billion in 2022. Thus, the above factors could be limiting the global diabetes drugs market's potential growth.

Segment Analysis

The global diabetes drugs market is segmented based on Drug Class, Diabetes Type, Route of Administration, Distribution Channel, and region.

Drug Class:

The GLP-1 receptor agonists segment is expected to dominate the global diabetes drugs market share

The GLP-1 receptor agonists segment holds a major portion of the global diabetes drugs market share and is expected to continue to hold a significant portion of the global diabetes drugs market share during the forecast period.

Glucagon-like peptide-1 (GLP-1) analogues, commonly known as GLP-1 receptor agonists or incretin mimetics, are a category of medications that replicate the actions of the naturally occurring hormone GLP-1. This hormone is secreted by the intestines after food consumption and is essential for glucose regulation. It enhances insulin secretion, inhibits glucagon release, and promotes feelings of fullness. These medications are mainly utilized to treat type 2 diabetes and obesity, as they effectively lower blood sugar levels and assist in weight loss by reducing appetite and caloric intake. These factors have driven the global diabetes drugs market expansion.

Furthermore, key players' strategies such as partnerships & collaborations, and product launches & approvals would drive the diabetes drugs market growth. For instance, in November 2023, AstraZeneca announced its strategic approach to the cardiometabolic market, particularly focusing on treating obesity and its associated co-morbidities. This strategy involves combining the recently acquired GLP-1 receptor agonist therapy from Eccogene, known as ECC5004, with their existing cardiometabolic therapies, specifically the sodium-glucose co-transporter-2 (SGLT2) inhibitor Farxiga (dapagliflozin).

Also, in March 2022, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved a new 2.0 mg dose of Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) analogue, for the treatment of adults with type 2 diabetes. This approval expands the available dosing options for Ozempic, which now includes 0.5 mg, 1.0 mg, and the newly approved 2.0 mg doses. These factors have solidified the segment's position in the global diabetes drugs market.

Geographical Analysis

North America is expected to hold a significant position in the global diabetes drugs market share

North America holds a substantial position in the global diabetes drugs market and is expected to hold most of the market share.

Diabetes Epidemiology in the U.S.

The rising incidence of type 2 diabetes is a primary driver of market growth in North America. According to the CDC, in 2021, approximately 38.4 million individuals of all ages, representing 11.6% of the U.S. population, were diagnosed with diabetes. Among adults aged 18 and older, this figure rose to 38.1 million, accounting for 14.7% of all U.S. adults.

Notably, 8.7 million adults in this age group met the laboratory criteria for diabetes but were either unaware of their condition or did not report it, which constitutes 3.4% of all U.S. adults and 22.8% of those with diabetes. The prevalence of diabetes among adults increases with age, reaching 29.2% for those aged 65 and older. Furthermore, rising obesity rates, technological advancements, government initiatives and support, and research and development drive this global diabetes drugs market growth.

Moreover, a major number of key player's presence, well-advanced healthcare infrastructure, and product launches & approvals would drive this global diabetes drugs market growth in this region. For instance, in June 2023, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) for use in children aged 10 and older with type 2 diabetes, as part of a treatment plan that includes diet and exercise. This marks the introduction of a new class of oral medications for pediatric type 2 diabetes management.

Also, in January 2023, TheracosBio announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. Brenzavvy is indicated as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes. It is not recommended for individuals with type 1 diabetes mellitus or the treatment of diabetic ketoacidosis.

In addition, key players more focus on the treatment for type-2, and innovative launches help to drive this market growth. For instance, in August 2023, Dr. Reddy's Laboratories launched Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market. This product is a generic equivalent of Kombiglyze XR (saxagliptin and metformin hydrochloride extended-release) tablets, which has received approval from the U.S. Food and Drug Administration (USFDA). Thus, the above factors are consolidating the region's position as a dominant force in the global diabetes drugs market.

Asia Pacific is growing at the fastest pace in the global diabetes drugs market share

Asia Pacific holds the fastest pace in the global diabetes drugs market and is expected to hold most of the market share.

The Asia-Pacific region is experiencing significant growth in the prevalence of diabetes, currently home to 60% of the global diabetic population. Notably, India and China account for approximately half of this figure. Other countries such as Indonesia, Thailand, and Japan are also witnessing an increase in diabetes cases.

Diabetes Epidemiology in Asia-Pacific

As per Abbott news in February 2022, India has the second-largest diabetes population globally, with recent studies indicating significant disruptions in healthcare for non-communicable diseases due to the pandemic. Up to 87% of individuals with diabetes have reduced their visits to healthcare providers, and less than half own a blood glucose monitoring device at home. For adults with type 2 diabetes who are on intensive insulin therapy, research has shown that using sensor-based devices for at least three months can lower average HbA1c levels from 8.9% to 8%.

According to the International Diabetes Federation (IDF) statistics from 2021, there are 90 million adults aged 20-79 living with diabetes in the South East Asia (SEA) region. Alarmingly, 46 million of these adults remain undiagnosed, and approximately 1 in 4 live births are affected by hyperglycemia during pregnancy. Similarly, in April 2024, a U.S. company introduced a diabetes educational program aimed at individuals in Singapore, reflecting a growing focus on diabetes management in the region. Projections by the IDF indicate that by 2045, the number of people living with diabetes could rise to 783 million globally.

Furthermore, key players in the region and product launches would drive this global diabetes drugs market growth. For instance, in October 2023, Glenmark Pharmaceuticals launched a triple-combination drug for the treatment of Type 2 diabetes, branded as Zita DM. This innovative medication is notable for being the first of its kind in India that combines three active ingredients into a single fixed-dose combination (FDC), aimed at improving glycemic control in adults with diabetes. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global diabetes drugs market.

Competitive Landscape

The major global players in the diabetes drugs market include Sanofi, Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, AstraZeneca., Bristol Myers Squibb, and GSK plc among others.

Key Developments

• In April 2024, Sanofi India officially launched its new diabetes medication, Soliqua, following the approval from the Central Drugs Standard Control Organization (CDSCO) last year. This drug is specifically designed for adults with obesity and type 2 diabetes mellitus, aimed at improving glycemic control as an adjunct to diet and exercise for those who have not achieved adequate control with existing oral or injectable therapies.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global diabetes drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.